FEB 2 4 2005

FAX TRANSMISSION
DATE: February 24, 2005
PTO IDENTIFIER: Application Number 09/996357-Conf. #1918 Patent Number Inventor: Malcolm L. GEFTER et al.
MESSAGE TO: US Patent and Trademark Office FAX NUMBER: (703) 872-9306
FROM: LAHIVE & COCKFIELD, LLP  Maria Laccotripe Zacharakis, Ph.D., J.D.  PHONE: (617) 227-7400  Attorney Dkt. #: PPI-105
PAGES (Including Cover Sheet): 13  CONTENTS: Amendment Transmuttal (1 page)
Amendment Response to Final Action (11 pages)
If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 227-7400 and send the original transmission to us by return mail at the address below.  This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.
LAHIVE & COCKFIELD, LLP 28 State Street, Boston, Massachusetts 02109 Telephone: (617) 227-7400 Facsimile: (617) 742-4214

AMENDMENT TRANSMITTAL LETTER Docket No. PPI-105						
Application No. 09/996357-Conf. #1918		Filing Date November 27, 2001		Examiner C. J. Nichol	Art Unit	
Applicant(s). Malcolm L. GEFTER et al.						
Invention: THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR TREATING ANAMYLOIDOGENIC DISEASE						
TO THE COMMISSIONER FOR PATENTS  Transmitted nerewith is an amendment in the above-identified application.  The fee has been calculated and is transmitted as shown below.						
	Claims	Highest	S AS AMEN	DED		
	Remaining After Amendment	Number Previously Paid	Number Extra Claims Present			
Total Claims	11	- 183 =	Fleatin	Rate X		
Independent Claims	2	- 4 =		x		
Multiple Dependent Claims (check if applicable)						
Other fee (please specify):						
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT: 0.00						
Large Entity x Small Entity						
× No additional fee is required for this amendment.						
Please charge Deposit Account No in the amount of \$  A duplicate copy of this sheet is enclosed.						
A check in the amount of \$ to cover the filing fee is enclosed.						
Payment by credit card. Form PTO-2038 is attached.						
The Director is hereby authorized to charge and credit Deposit Account No. 12-0080 as described below. A duplicate copy of this sheet is enclosed.						
Credit any overpayment.						
x Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.						
XXXXXX						
Maria Laccotripe Zacharakis, Ph.D., J.D. Attorney Reg. No.: 56,266						
LAHIVE & COCKFIELD, LLP						
28 State Street Boston, Massachusetts 02109						
(617) 227-7400						
I nereby certify that this correspondence is being facsimile transmitted to the Patent and Trademan Office, facsimile no. (703) 872- 9306 at MF AF, Commissioner for Patents. P.O. Box 450, Plexandria, VA 22313-450, on the date shown below.						
Dated. February 24, 2005 Signature: W. L. D. J.						

24-Feb-05 03:26pm From-LAHIVE & COCKFIELD, LLP

6177424214

T-599 P.03/13 F-722

I hereby ceruly that this correspondence is being tacsimile transmitted to the Patient and Trademath Office, tacsimile no. (703) 872-9306 at MS AF, Commissioner for Patients, P.O. Box 1450, Alexandria, V.p. 22313-1450, on the

Dated February 24, 2005 Signature

(Mana Laccorana Zantara)

Docket No.: PPI-105

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 2 4 2005

In re Patent Application of: Malcolm L. Gefter et al.

CENTRAL FAX CENTER

Application No.: 09/996357

Confirmation No.: 1918

Filed: November 27, 2001

Art Unit: 1647

For: THERAPEUTIC AGENTS AND METHODS

Examiner:

OF USE THEREOF FOR TREATING AN

NICHOLS, CHRISTOPHER J

AMYLOIDOGENIC DISEASE

## AMENDMENT RESPONSE TO FINAL OFFICE ACTION

MS AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Final Office Action mailed November 24, 2004, please amend the application as follows:

Amendments to the Claims are reflected in the listing of the claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.